Effectiveness of epoprostenol in the management of pulmonary arterial hypertension: findings of an Australian retrospective chart review

摘要

Background: Pulmonary arterial hypertension (PAH) is a progressively fatal disease. Parenteral prostanoids, including intravenous (IV) epoprostenol, are the most effective therapies for PAH. As epoprostenol requires continuous infusion, therapy is challenging and use is managed by specialist units.